Suppr超能文献

开发具有改善的肾脏清除行为的 F-氟代糖基 PSMA 配体。

Development of F-Fluoroglycosylated PSMA-Ligands with Improved Renal Clearance Behavior.

机构信息

Department of Nuclear Medicine, Molecular Imaging and Radiochemistry, Friedrich-Alexander University (FAU), Schwabachanlage 12, 91054 Erlangen, Germany.

出版信息

Mol Pharm. 2020 Mar 2;17(3):933-943. doi: 10.1021/acs.molpharmaceut.9b01179. Epub 2020 Feb 17.

Abstract

The prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly expressed in the malignant human prostate epithelium. Therefore, PSMA has emerged as a very attractive target for developing radiopharmaceuticals for the diagnosis, e.g., by positron emission tomography (PET) imaging, and radiotherapy of prostate cancer. The aim of this study was to develop F-labeled PSMA ligands bearing different F-glycosyl moieties to study the effect on the clearance behavior of radiotracers in addition to their tumor binding ability. Therefore, we applied click chemistry-based F-fluoroglcosylation using 2-deoxy-2-[F]fluoroglucosyl azide or 6-deoxy-6-[F]fluoroglucosyl azide as prosthetic groups for the radiosynthesis of the F-fluoroglycosylated glutamate-urea-lysine-based PSMA inhibitors 2-[F]FGlc-PSMA ([F]) and 6-[F]FGlc-PSMA ([F]). The PSMA inhibitory potencies were determined by competitive radioligand binding assays using Tc-MIP-1404 and PSMA-expressing PC-3 PIP cells, revealing moderate PSMA inhibitory potencies for [F] (IC = 234 nM) and [F] (IC = 59 nM). Biodistribution and small-animal PET studies were performed using PSMA-positive PC-3 PIP and PSMA-negative PC-3 tumor-bearing nude mice. PSMA inhibitors [F] and [F] were obtained in high radioactivity yields of 19-22% (nondecay-corrected, referred to [F]fluoride) and with molar activities of 71-136 GBq/μmol. In the biodistribution studies, the uptake levels of [F] and [F] in PC-3 PIP tumors were 13 ± 3%ID/g and 6 ± 5%ID/g at 60 min p.i., respectively. PSMA-negative PC-3 tumors and all other tissues had negligible low uptake values. Interestingly, [F] had high uptake in the kidneys, with remarkable retention from 30 to 60 min p.i. (74 to 72%ID/g). In contrast, [F] revealed a low uptake of 7.5%ID/g in the kidneys at 30 min p.i. and was rapidly cleared through the kidney (0.9%ID/g at 120 min p.i.). In direct comparison to a Ga-PSMA-11 PET scan of the same mouse, [F] and [F] showed 2- to 3-fold higher uptake values in PC-3 PIP tumors. Both radiotracers were solely cleared via the kidneys and not via the hepatobiliary pathway. The regional kidney distribution pattern of the tracers in the kidneys revealed that Ga-PSMA-11 and 2-[F]FGlc-PSMA([F]) mainly accumulated in the cortex of the kidneys, whereas 6-[F]FGlc-PSMA([F]) showed a 10-fold lower kidney uptake with accumulation in the inner medulla or pelvis of the kidneys. Overall, the developed 6-fluoroglucosyl derivative [F], with its considerably low kidney uptake and fast clearance, demonstrated high uptake in PSMA-positive tumors This candidate could, therefore, be valuable for translation into the clinic.

摘要

前列腺特异性膜抗原(PSMA)是一种 II 型跨膜糖蛋白,在恶性人前列腺上皮中高度表达。因此,PSMA 已成为开发用于前列腺癌诊断(例如通过正电子发射断层扫描(PET)成像)和放射治疗的放射性药物的非常有吸引力的靶标。本研究的目的是开发带有不同 F-糖基部分的 F 标记的 PSMA 配体,以研究放射性示踪剂清除行为的影响,除了它们的肿瘤结合能力。因此,我们应用基于点击化学的 F-氟糖基化,使用 2-脱氧-2-[F]氟葡萄糖基叠氮化物或 6-脱氧-6-[F]氟葡萄糖基叠氮化物作为前体基团,用于 F-氟糖基化谷氨酸-脲-赖氨酸基 PSMA 抑制剂 2-[F]FGlc-PSMA([F])和 6-[F]FGlc-PSMA([F])的放射性合成。通过使用 Tc-MIP-1404 和表达 PSMA 的 PC-3 PIP 细胞进行竞争性放射性配体结合测定,确定了 PSMA 的抑制效力,结果表明[F](IC=234 nM)和[F](IC=59 nM)具有中等的 PSMA 抑制效力。使用 PSMA 阳性 PC-3 PIP 和 PSMA 阴性 PC-3 荷瘤裸鼠进行了生物分布和小动物 PET 研究。PSMA 抑制剂[F]和[F]以 19-22%(未衰变校正,参照[F]氟化物)的高放射性产率和 71-136GBq/μmol 的摩尔活性获得。在生物分布研究中,[F]和[F]在 PC-3 PIP 肿瘤中的摄取水平分别为 13±3%ID/g 和 6±5%ID/g,在 60 分钟时。PSMA 阴性 PC-3 肿瘤和所有其他组织的摄取值均较低。有趣的是,[F]在肾脏中的摄取水平很高,从 30 分钟到 60 分钟的保留率为 74%至 72%(ID/g)。相比之下,[F]在 30 分钟时肾脏的摄取率仅为 7.5%ID/g,并且通过肾脏迅速清除(120 分钟时为 0.9%ID/g)。与同一小鼠的 Ga-PSMA-11 PET 扫描直接比较,[F]和[F]在 PC-3 PIP 肿瘤中的摄取值高 2-3 倍。两种示踪剂均仅通过肾脏清除,而不是通过肝胆途径清除。示踪剂在肾脏中的区域肾脏分布模式表明,Ga-PSMA-11 和 2-[F]FGlc-PSMA([F])主要积聚在肾脏的皮质中,而 6-[F]FGlc-PSMA([F])则显示出 10 倍的较低的肾脏摄取量,积聚在肾脏的内髓质或肾盂中。总体而言,开发的 6-氟葡萄糖基衍生物[F],由于其肾脏摄取量低且清除速度快,在 PSMA 阳性肿瘤中具有高摄取量。该候选物因此可能对转化为临床具有价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验